I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice